Salud financiera de hoja de balance de NexImmune

Salud financiera controles de criterios 3/6

NexImmune tiene un patrimonio de los accionistas total de $696.4K y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $5.9M y $5.2M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$2.42m
Patrimonio	US$696.35k
Total pasivo	US$5.16m
Activos totales	US$5.86m

Actualizaciones recientes sobre salud financiera

Recent updates

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Sep 07

Neximmune GAAP EPS of -$0.69 misses by $0.01

Aug 15

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

Jul 14

NexImmune: Selling For Under Cash Value

May 31

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

May 26

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Dec 19

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($3.1M) de NEXI no cubren sus pasivos a corto plazo ($4.7M).

Pasivo a largo plazo: Los activos a corto plazo de NEXI ($3.1M) superan a sus pasivos a largo plazo ($428.4K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: NEXI está libre de deudas.

Reducción de la deuda: NEXI no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NEXI tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: NEXI tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 7% cada año

Salud financiera de hoja de balance de NexImmune

Salud financiera controles de criterios 3/6

Información clave

Actualizaciones recientes sobre salud financiera

The Nasdaq Stock Market to Delist Common Stock of NexImmune

Nasdaq Determines to Delist NexImmune Shares of Common Stock

Nasdaq Determines to Delist NexImmune Shares of Common Stock

NexImmune, Inc. announced delayed 10-Q filing

NexImmune, Inc. announced delayed annual 10-K filing

NexImmune Receives Notice from Nasdaq Pursuant to Nasdaq Listing Rule 5101

Recent updates

The Nasdaq Stock Market to Delist Common Stock of NexImmune

Nasdaq Determines to Delist NexImmune Shares of Common Stock

Nasdaq Determines to Delist NexImmune Shares of Common Stock

NexImmune, Inc. announced delayed 10-Q filing

NexImmune, Inc. announced delayed annual 10-K filing

High number of new directors

NexImmune, Inc. has completed a Follow-on Equity Offering in the amount of $3.672009 million.

NexImmune Receives Notice from Nasdaq Pursuant to Nasdaq Listing Rule 5101

NexImmune, Inc. announced delayed 10-Q filing

NexImmune Regains Compliance with the Minimum Closing Bid Price Requirement

NexImmune, Inc. Approves 1 for 25 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

NexImmune, Inc. Announces Executive Changes, Effective as of September 2, 2023

NexImmune, Inc. Announces John Trainer, Chief Financial Officer to Depart, Effective September 2, 2023

New major risk - Financial position

Neximmune Announces Initial Positive Data from the NEXI-001 Phase 1 Trial for Relapsed/Refractory Post Allo-Hsct Aml At the American Society of Clinical Oncology 2023 Annual Meeting

Independent Chairman of the Board recently bought US$164k worth of stock

Price target decreased by 30% to US$2.43

High number of new directors

Independent Chairman of the Board recently bought US$96k worth of stock

Price target decreased to US$2.43

High number of new directors

NexImmune Receives Deficiency Letter from the Listing Qualifications Department of Nasdaq

NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely

Neximmune GAAP EPS of -$0.69 misses by $0.01

NexImmune Announces IND Clearance by the US FDA for NEXI-003 for the Treatment of HPV-Related Cancers

NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers

NexImmune, Inc.(NasdaqGM:NEXI) dropped from Russell 2500 Value Index

Independent Director recently bought US$298k worth of stock

Price target decreased to US$14.75

NexImmune: Selling For Under Cash Value

Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation

NexImmune Inc. Appoints Leena Gandhi to Board of Directors as a Non-Executive Director

NexImmune, Inc., Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Neximmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center's Herbert Irving Comprehensive Cancer Center

Neximmune, Inc. Promotes Mathias Oelke, Ph.D., to Chief Scientific Officer

NexImmune, Inc. Announces Management Changes

Independent Director exercised options to buy US$338k worth of stock.

We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate

Independent Director has left the company

NexImmune, Inc. has completed an IPO in the amount of $110.007 million.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera